Related Experiment Video

Updated: Dec 10, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K

The Long Non-Coding RNA IDH1-AS1 Promotes Prostate Cancer Progression by Enhancing IDH1 Enzyme Activity

Shuo Wu1, Liucheng Ding1, Hewei Xu1

  • 1Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Oncotargets and Therapy
|September 5, 2020
PubMed
Abstract

Insights

Long non-coding RNA IDH1-AS1 promotes prostate cancer by altering IDH1 enzyme activity. This study identifies IDH1-AS1 as a potential therapeutic target for prostate cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) play a role in tumor development.
  • Prostate cancer involves complex molecular mechanisms.
  • IDH1-AS1 is a natural antisense RNA with potential roles in cancer.

Purpose of the Study:

  • To investigate the function of IDH1-AS1 in prostate cancer.
  • To explore the novel molecular mechanisms underlying IDH1-AS1's carcinogenic effects.
  • To determine if IDH1-AS1 impacts IDH1 gene expression or enzyme activity.

Main Methods:

  • Expression analysis using GEPIA and CCLE databases, validated by RT-qPCR.
  • Functional assays including CCK-8, EdU, and transwell assays.
  • Molecular mechanism exploration via RT-qPCR, Western blot, and IDH1 enzyme activity assays.

Main Results:

  • IDH1-AS1 expression is significantly elevated in prostate cancer tissues and cell lines.
  • Knockdown of IDH1-AS1 inhibits prostate cancer cell proliferation and migration.
  • IDH1-AS1 regulates IDH1 enzyme activity without affecting IDH1 mRNA or protein levels.

Conclusions:

  • The carcinogenic effects of IDH1-AS1 in prostate cancer are linked to a novel mechanism involving direct alteration of IDH1 enzyme activity.
  • IDH1-AS1 represents a new potential therapeutic target for prostate cancer.
  • Further research into IDH1-AS1's role could lead to innovative treatment strategies.
Keywords:
antisense RNAbioinformatics analysisdivergent transcriptionenzyme activity

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.3K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.2K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.1K